Northwest Biotherapeutics (NWBO) Other Non-Current Assets (2010 - 2026)

Northwest Biotherapeutics' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $354000.0 for Q1 2026.

• In Q1 2026, Other Non-Current Assets fell 3.54% year-over-year to $354000.0; the TTM figure through Mar 2026 stood at $354000.0 (down 3.54% YoY), while the FY2025 annual figure was $356000.0, down 2.47% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $354000.0, down from $356000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $374000.0 in Q3 2024, with the low at $339000.0 in Q3 2022.
• The 5-year median for Other Non-Current Assets is $361000.0 (2023), against an average of $358529.4.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets plunged 68.71% in 2022, then increased 5.56% in 2023.
• Northwest Biotherapeutics' Other Non-Current Assets stood at $345000.0 in 2022, then increased by 4.64% to $361000.0 in 2023, then advanced by 1.11% to $365000.0 in 2024, then dropped by 2.47% to $356000.0 in 2025, then retreated by 0.56% to $354000.0 in 2026.
• Business Quant data shows NWBO's Other Non-Current Assets at $354000.0 in Q1 2026, $356000.0 in Q4 2025, and $358000.0 in Q3 2025.